Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Experts in Med Tech Regulation and Surgical Technologies join the Medical Sciences Division Industry Experts in Residence Scheme.

Dr Toni Day (left) and Professor Chris Cheng (right)

The Business Development Team for the Medical Sciences Division has announced the appointment of two new  experts to its Industry Experts in Residence Scheme. Dr Toni Day, Director of Quality and Regulatory Affairs at OrganOx, and Professor Chris Cheng, Consulting Professor in Vascular Surgery at Stanford and CEO of medical device company Koli Inc., became part of the scheme in December. 

The Industry Experts in Residence programme is managed by the MSD Business Development Team and Oxford University Innovation. It aims to give Oxford's research community access to world-leading expertise and advice across multiple sectors. Researchers can arrange meetings with industry experts to discuss their ideas and projects, and attend seminars give by these experts on a wide range of topics.

The scheme currently hosts experts in product design in biomedical engineering, drug discovery, and digital health, and the appointment of Dr Day and Professor Cheng has now made their expertise in Med Tech Regulation and Surgical Technologies available to researchers.

Dr Day holds a BSc Honours degree in Biochemistry and a DPhil in Neuropharmacology from the University of Oxford, and has worked for a number of start-up companies in the medical device, in vitro diagnostics and pharmaceutical arenas. She joined OrganOx Ltd in April 2011 to build the Quality Management System and the Regulatory Strategy. Toni commented: 'I am delighted to be part of the Industry Experts in Residence Scheme, and look forward to meeting researchers to discuss medical devices at all levels of the development lifecycle.' She is hosted in Oxford by the Oxford Medical CE Marking Forum (OxMCEF)

Professor Cheng is currently CEO of Koli, Inc., a medical device company developing a catheter-based solution for gallstone disease (spun out of Stanford Biodesign). He is also a Consulting Professor in Vascular Surgery at Stanford. He commented: 'I am thrilled to be at Oxford as part of the Expert in Residence program!  My colleagues in Surgery and Cardiovascular Medicine, as well as the Fellows at Exeter College, have made me feel at home since day one.  While I am here, I look forward to learning about the NHS, and am especially excited about engaging with students and faculty about academic collaborations with the medical device industry.' 

Maxine Allen, Head of Business Development and Partnering for the Medical Sciences Division, commented: 'The Industry Experts in Residence scheme is a fantastic opportunity for our researchers to develop translational strategies for their projects, and an innovative way to foster interaction between industry and academia.'

Find out more about the scheme and book an appointment with an expert 

______________________________________________________________________________________________

Upcoming workshops and talks

Professor Cheng will be running open, small group sessions about biomedical research, the medical device industry, entrepreneurship, choosing between academia and industry, and work-life balance over the coming term. These sessions will be from 2.30-4.30pm on Thurs 25 Jan, Thurs 8 Feb, Thurs 22 Feb, and Thurs 8 March in Exeter College Cohen Quad. Please send Prof. Cheng an email (christopher.cheng@exeter.ox.ac.uk) to confirm a place.  

Further workshops and events: 

Similar stories

Investigating New Treatment for Schizophrenia

General Innovation Research

A partnership between University of Oxford, the Earlham Institute, and the global pharmaceutical companies Biogen Inc and Boehringer Ingelheim is announced today to investigate a new drug target for the treatment of schizophrenia.

£100 million donation from Ineos to create new institute to fight antimicrobial resistance

Awards and Appointments General Innovation

A new state of the art institute for antimicrobial research is to open at Oxford University thanks to a £100 million donation from Ineos.

University spinout PepGen awarded major financing to target Duchenne muscular dystrophy

Awards and Appointments General Innovation

PepGen, a therapeutics company targeting severe neuromuscular diseases, including Duchenne muscular dystrophy (DMD), has closed a $45 million Series A funding round led by RA Capital Management with participation from Oxford Sciences Innovation (OSI), the company’s original seed investor.

Evox Therapeutics announces launch of strategic collaboration with the University of Oxford

General Innovation

Collaboration with world-renowned research centre to accelerate development of exosome therapies for rare diseases

BioEscalator’s resident biotech Base Genomics acquired by Exact Sciences

General Innovation

Oxford Sciences Innovation (OSI) recently announced the acquisition of its portfolio company, Base Genomics, by US-based early cancer diagnostic leaders, Exact Sciences, for $410m. The partnership will enable Base Genomics to significantly accelerate its clinical and commercial development here in Oxford, potentially unlocking a new era of preventative medicine and improved patient outcomes.